Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide(TM) Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Stock Information for PLUS THERAPEUTICS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PLUS THERAPEUTICS Inc.

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT   
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ(TM) in Leptomeningeal Metastases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.